Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East‐Asian patients with type 2 diabetes in a multicentre, double‐blind, randomized, parallel‐arm, active comparator, phase III trial

AIMS: To compare the efficacy and safety of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide 1.5 and 0.75 mg with glimepiride in East‐Asian patients with type 2 diabetes (T2D). MATERIALS AND METHODS: In this phase III, multinational, multicentre, double‐blind, randomized, parallel‐ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yu Hong, Huang, Chien‐Ning, Cho, Young Min, Li, Pengfei, Gu, Liqun, Wang, Feng, Yang, Jun, Wang, Wei Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099453/
https://www.ncbi.nlm.nih.gov/pubmed/29708650
http://dx.doi.org/10.1111/dom.13340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099453/
https://www.ncbi.nlm.nih.gov/pubmed/29708650
http://dx.doi.org/10.1111/dom.13340

Ejemplares similares